USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
SAVARA, INC.
Address:
900 S. Capital of Texas Hwy
Suite 150
Austin, TX 78746
Phone:
N/A
URL:
EIN:
260456317
DUNS:
801937272
Number of Employees:
6
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $524,251.00 3
SBIR Phase II $3,986,098.00 1

Award List:

A High Efficiency Corticosteroid Dry Powder Inhaler for Pediatric Use

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$184,148.00
Agency:
HHS
Principal Investigator:
Taneli Jouhikainen – 785-550-0672
Abstract:
DESCRIPTION (provided by applicant): Asthma is a chronic respiratory disease with a global human and economic burden on patients, and society. Asthma treatment mainly consists of inhaled corticosteroids and bronchodilators, which enable adult populations to function well despite the disease. Small… More

Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$149,750.00
Agency:
HHS
Principal Investigator:
Taneli Jouhikainen – 512-632-7537
Abstract:
DESCRIPTION (provided by applicant): Savara Inc. is developing a novel inhaled dry-powder form of vancomycin (AEROVANC) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection, initially in cystic fibrosis (CF) patients and subsequently in other high risk patient… More

Targeted nanoparticle gene therapy for lung cancer

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$190,353.00
Agency:
HHS
Principal Investigator:
Taneli Jouhikainen – 512-632-7537
Abstract:
DESCRIPTION (provided by applicant): Project Summary A transformational NanoNucleic delivery technology is being investigated by Savara Inc. as a promising first-in-class gene therapy candidate for lung cancer. A potent lung cancer therapy with fewer sideeffects is urgently needed due to the… More

Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$3,986,098.00
Agency:
HHS
Principal Investigator:
Taneli Jouhikainen – 512-614-1848
Abstract:
DESCRIPTION (provided by applicant): Persistent respiratory methicillin-resistant Staphylococcus aureus (MRSA) infections have become increasingly common in cystic fibrosis (CF) patients, with a prevalence of almost 30% in CF patients in the US. This is concerning, as MRSA positivity is associated… More